Oncolytics Biotech Inc (ONC):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Oncolytics Biotech Inc (ONC) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7375
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Oncolytics Biotech Inc (Oncolytics) is a development stage biopharmaceutical company which focuses on the discovery and development of oncolytic viruses for the treatment of cancer. The company’s lead product, Reolysin, a formulation of the human reovirus, is indicated for the treatment of lung, ovarian, colorectal, pancreatic, prostate, breast, head and neck cancers. Reolysin is also undergoing various other clinical trials to determine its use in other types of cancer, such as for squamous cell carcinoma, metastatic colorectal cancer, metastatic melanoma trial, and non-small cell lung cancer. The company and its partners conduct clinical trials across Canada and the US. Oncolytics is headquartered in Calgary, Alberta, Canada.

Oncolytics Biotech Inc (ONC) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Oncolytics Biotech Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Oncolytics Biotech Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Oncolytics Biotech Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Oncolytics Biotech Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Oncolytics Biotech Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Oncolytics Biotech Inc, Medical Equipment, Deal Details 10
Private Equity 10
Oncolytics Biotech to Raise up to USD26 Million in Private Placement of Shares 10
Equity Offering 11
Oncolytics Biotech Raises USD8.9 Million in Public Offering of Share 11
Oncolytics Biotech Raises USD8.5 Million in Public Offering of Units 12
Oncolytics Biotech Completes First Tranche Of Private Placement Of Shares For US$1 Million 14
Oncolytics Biotech Completes Public Offering Of Common Stock For US$32 Million 15
Oncolytics Biotech Completes Private Placement Of Shares For US$21 Million 16
Oncolytics Biotech Inc – Key Competitors 18
Oncolytics Biotech Inc – Key Employees 19
Oncolytics Biotech Inc – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Strategy And Business Planning 21
Jun 27, 2017: Oncolytics Biotech Opens U.S. Based Office in San Diego 21
Financial Announcements 22
Aug 03, 2018: Oncolytics Biotech reports 2018 second quarter results 22
May 11, 2018: Oncolytics Biotech Reports 2018 First Quarter Results 23
Mar 09, 2018: Oncolytics Biotech Announces 2017 Year End Results 24
Aug 03, 2017: Oncolytics Biotech Announces 2017 Second Quarter Results 26
May 05, 2017: Oncolytics Biotech Announces 2017 First Quarter Results 27
Mar 10, 2017: Oncolytics Biotech Announces 2016 Year-End Results 28
Corporate Communications 29
Apr 17, 2018: Oncolytics Biotech Announces Resignation Of Andres Gutierrez As Chief Medical Officer 29
Jan 25, 2018: Oncolytics Biotech Named to the 2018 OTCQX Best 50 30
Jun 29, 2017: Oncolytics Biotech Appoints Andrew de Guttadauro, President of Oncolytics Biotech 31
Jan 19, 2017: Oncolytics Biotech Appoints Dr. Matt Coffey to the Role of President and CEO 32
Legal and Regulatory 33
Jun 01, 2018: Oncolytics Biotech Announces Listing on Nasdaq Capital Market 33
May 29, 2018: Oncolytics Biotech Announces New OTCQX Ticker Symbol 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Oncolytics Biotech Inc, Medical Equipment, Key Facts, 2017 2
Oncolytics Biotech Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Oncolytics Biotech Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Oncolytics Biotech Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Oncolytics Biotech Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Oncolytics Biotech Inc, Deals By Market, 2012 to YTD 2018 8
Oncolytics Biotech Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Oncolytics Biotech to Raise up to USD26 Million in Private Placement of Shares 10
Oncolytics Biotech Raises USD8.9 Million in Public Offering of Share 11
Oncolytics Biotech Raises USD8.5 Million in Public Offering of Units 12
Oncolytics Biotech Completes First Tranche Of Private Placement Of Shares For US$1 Million 14
Oncolytics Biotech Completes Public Offering Of Common Stock For US$32 Million 15
Oncolytics Biotech Completes Private Placement Of Shares For US$21 Million 16
Oncolytics Biotech Inc, Key Competitors 18
Oncolytics Biotech Inc, Key Employees 19
Oncolytics Biotech Inc, Other Locations 20
Oncolytics Biotech Inc, Subsidiaries 20

List of Figures
Oncolytics Biotech Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Oncolytics Biotech Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Oncolytics Biotech Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Oncolytics Biotech Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Oncolytics Biotech Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Oncolytics Biotech Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Oncolytics Biotech Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Oncolytics Biotech Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[Oncolytics Biotech Inc (ONC):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • ESSA Pharma Inc (EPI)-製薬・医療分野:企業M&A・提携分析
    Summary Essa Pharma Inc (Essa Pharma) is a clinical-stage pharmaceutical company that carries out the development of small molecule drugs for the treatment castration-resistant prostate cancer (CRPC). The company’s lead product candidate, EPI-506, disrupts androgen receptor (AR) transcriptional acti …
  • United Bank Of India
    United Bank Of India - Strategy, SWOT and Corporate Finance Report Summary United Bank Of India - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Morphotek Inc-製薬・医療分野:企業M&A・提携分析
    Summary Morphotek Inc (Morphotek), a subsidiary of Eisai Co Ltd is a clinical-stage biotech company that develops novel classes of biological based products. The company offers a pipeline of monoclonal antibodies, antibody drug conjugates, and bispecific antibodies for the treatment of cancer, infla …
  • Merck & Co., Inc.:企業の戦略・SWOT・財務情報
    Merck & Co., Inc. - Strategy, SWOT and Corporate Finance Report Summary Merck & Co., Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Leigh Creek Energy Ltd (LCK):企業の財務・戦略的SWOT分析
    Leigh Creek Energy Ltd (LCK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Hilton Worldwide Holdings Inc:企業の戦略・SWOT・財務情報
    Hilton Worldwide Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary Hilton Worldwide Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Volta River Authority:企業の戦略的SWOT分析
    Volta River Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Israel Chemicals Ltd (ICL):企業の財務・戦略的SWOT分析
    Israel Chemicals Ltd (ICL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • NanoViricides Inc (NNVC)-製薬・医療分野:企業M&A・提携分析
    Summary NanoViricides Inc (NanoViricides), formerly Edot-com.com Inc is a biopharmaceutical company that provides nanomedicine technology solutions. The company conducts research in the areas of medical science and pharmaceutical technology such as polymeric micelles, multi-specific multi-targeting, …
  • Juvenile Diabetes Research Foundation:製薬・医療:M&Aディール及び事業提携情報
    Summary Juvenile Diabetes Research Foundation (JDRF) is a research organization that offers funding services for type 1 diabetes. The organization conducts clinical trials for curing, preventing and treating for type 1 diabetes and its complications; and researching new drugs for patients to manage …
  • National Gas & Industrial Co. (2080):企業の財務・戦略的SWOT分析
    National Gas & Industrial Co. (2080) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • China Huaneng Group:企業の発電所・SWOT分析2018
    China Huaneng Group - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees …
  • CSL Ltd (CSL):製薬・医療:M&Aディール及び事業提携情報
    Summary CSL Ltd (CSL) discovers, develops, manufactures, markets and distributes biopharmaceuticals and related products. Its portfolio encompasses plasma-derived products for the treatment of bleeding disorders such as hemophilia and von Willebrand disease, hereditary angioedema, primary and second …
  • Ampio Pharmaceuticals Inc (AMPE):製薬・医療:M&Aディール及び事業提携情報
    Summary Ampio Pharmaceuticals Inc (Ampio), formerly Chay Enterprises Inc is a biopharmaceutical company that discovers and develops novel therapeutic candidates for inflammatory conditions. The company develops compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by …
  • Callon Petroleum Co (CPE):石油・ガス:M&Aディール及び事業提携情報
    Summary Callon Petroleum Co (CPC) is an oil and gas company that offers building reserves and production of onshore and offshore oil and natural gas. The company carries out acquisition, development, exploration, and exploitation of unconventional onshore, oil, and natural gas reserves. It operates …
  • Diebold Nixdorf, Incorporated:戦略・SWOT・企業財務分析
    Diebold Nixdorf, Incorporated - Strategy, SWOT and Corporate Finance Report Summary Diebold Nixdorf, Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Astron Corporation Ltd (ATR):企業の財務・戦略的SWOT分析
    Astron Corporation Ltd (ATR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Abionic SA-医療機器分野:企業M&A・提携分析
    Summary Abionic SA (Abionic) is a medical device company that develops, produces, and markets in vitro diagnostic devices. The company offers products such as abioSCOPE, IVD capsule, abioGUIDE, abioGUIDE application for android, iPhone & iPad, and accessories. Its abioSCOPE in vitro tests are design …
  • Full House Resorts, Inc.:企業の戦略・SWOT・財務情報
    Full House Resorts, Inc. - Strategy, SWOT and Corporate Finance Report Summary Full House Resorts, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • AGILeBiotics BV:製薬・医療:M&Aディール及び事業提携情報
    Summary AGILeBiotics BV (AGILeBiotics) is a pharmaceutical company that focus on the discovery and development of new antibiotics to treat multi-drug resistant infections. The company’s patented synthetic method technology OxaSelect transforms the currently available antibiotics, which became less e …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆